ArticleBritish journal of cancer2016
Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival.
Article in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 83 citations in OpenAlex.
- Immunohistochemical evaluation of androgen receptor expression in endometrial carcinoma and its clinicopathological significance.Diagnostic pathology · 2026Article
- A Thematic Narrative Review of Osteoarthritis Risk Factors Across the Female Life Course.International journal of molecular sciences · 2026Review
- Article
- Methodological Pitfalls in Endometriosis Biospecimen Research: Lessons From MAP4K4 Expression Studies.FASEB bioAdvances · 2026Article
- Compound design of a patient-derived 3D cell culture system modelling early peritoneal endometriosis.Disease models & mechanisms · 2026Article
- Selecting Optimal Housekeeping Genes for RT-qPCR in Endometrial Cancer Studies: A Narrative Review.International journal of molecular sciences · 2025Review
- Article
- Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.Nature reviews. Cancer · 2025Review
- Hormone receptor profile of ectopic and eutopic endometrium in adenomyosis: a systematic review.Human reproduction open · 2025Article
- Functional, patient-derived 3D tri-culture models of the uterine wall in a microfluidic array.Human reproduction (Oxford, England) · 2024Article
- Androgen-responsive FOXP4 is a target for endometrial carcinoma.Communications biology · 2024Article
- Pre-receptor regulation of 11-oxyandrogens differs between normal and cancerous endometrium and across endometrial cancer grades and molecular subtypes.Frontiers in endocrinology · 2024Article
- RNA modification regulator DDC in endometrial cancer affects the tumor microenvironment and patient prognosis.Scientific reports · 2023Article
- Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.Endocrinology · 2023Review
- Androgens in endometrial carcinoma: the killer or helper?Journal of endocrinological investigation · 2023Review
- What Role do Androgens Play in Endometrial Cancer?Journal of personalized medicine · 2023Review
- The association of Wnt-signalling and EMT markers with clinical characteristics in women with endometrial cancer.Frontiers in oncology · 2023Article
- Androgen Signaling in Uterine Diseases: New Insights and New Targets.Biomolecules · 2022Review
- Hormonal regulation of telomerase activity and hTERT expression in steroid-regulated tissues and cancer.Cancer cell international · 2022Review
- Molecular Regulation of Androgen Receptors in Major Female Reproductive System Cancers.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial cancer (EC) is a hormone-driven disease, and androgen receptor (AR) expression in high-grade EC (HGEC) and metastatic EC has not yet been described.
methodsThe expression pattern and prognostic value of AR in relation to oestrogen (ERα and ERβ) and progesterone (PR) receptors, and the proliferation marker Ki67 in all EC subtypes (n = 85) were compared with that of healthy and hyperplastic endometrium, using immunohistochemisty and qPCR.
resultsCompared with proliferative endometrium, postmenopausal endometrtial epithelium showed significantly higher expression of AR (P < 0.001) and ERα (P = 0.035), which persisted in hyperplastic epithelium and in low-grade EC (LGEC). High-grade EC showed a significant loss of AR (P < 0.0001), PR (P < 0.0001) and ERβ (P < 0.035) compared with LGEC, whilst maintaining weak to moderate ERα. Unlike PR, AR expression in metastatic lesions was significantly (P = 0.039) higher than that in primary tumours. Androgen receptor expression correlated with favourable clinicopathological features and a lower proliferation index. Loss of AR, with/without the loss of PR was associated with a significantly lower disease-free survival (P < 0.0001, P < 0.0001, respectively).
conclusionsPostmenopausal endometrial epithelium acquires AR whilst preserving other steroid hormone receptors. Loss of AR, PR with retention of ERα and ERβ may promote the unrestrained growth of HGEC. Androgen receptor may therefore be a clinically relevant prognostic indicator and a potential therapeutic target in EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.